We are live on
!
Find out more
TCG Crossover Management Portfolio holdings
AUM
$4.16B
Turnover
31.15%
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter
Est. Return
+22.55%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$679M
AUM Growth
+$69.3M
(+11%)
Cap. Flow
+$84.1M
Cap. Flow
% of AUM
12.38%
Top 10 Holdings %
Top 10 Hldgs %
61.79%
Holding
30
New
8
Increased
3
Reduced
2
Closed
4
Avg Time Held
0.7
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Structure Therapeutics
GPCR
|
+$37.1M |
| 2 |
Inhibrx, Inc. Common Stock
INBX
|
+$36.6M |
| 3 |
Savara
SVRA
|
+$35.7M |
| 4 |
Compass Pathways
CMPS
|
+$34.2M |
| 5 |
Taysha Gene Therapies
TSHA
|
+$20.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$96.3M |
| 2 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$52.9M |
| 3 |
Immunovant
IMVT
|
+$7.23M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$5.49M |
| 5 |
Alpine Immune Sciences Inc
ALPN
|
+$2.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Structure Therapeutics
GPCR
$1.58B
| $75.8M | 11.16% |
1,502,747
+1,152,747
| +329% | +$37.1M |
2023 Q1
2 quarters
|
|
2
Cogent Biosciences
COGT
$5.06B
| $54.9M | 8.08% |
5,631,042
| – | – |
2021 Q4
7 quarters
|
|
3
Geron
GERN
$790M
| $49.6M | 7.3% |
23,375,839
-213,940
| -0.9% | -$581K |
2022 Q1
6 quarters
|
|
4
AN2 Therapeutics
ANTX
$137M
| $43.1M | 6.34% |
2,678,209
+1,388,889
| +108% | +$15.7M |
2023 Q2
1 quarter
|
|
|
5
Savara
SVRA
$994M
| $37.8M | 5.57% |
+10,000,000
| New | +$35.7M |
2023 Q3
0 quarters
|
|
|
6
Taysha Gene Therapies
TSHA
$1.21B
| $35.1M | 5.17% |
+11,111,111
| New | +$20.8M |
2023 Q3
0 quarters
|
|
7
DELISTED
KalVista Pharmaceuticals
KALV
| $32.7M | 4.81% |
3,395,495
| – | – |
2022 Q4
3 quarters
|
|
|
8
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $32.1M | 4.73% |
+1,750,387
| New | +$36.6M |
2023 Q3
0 quarters
|
|
9
Jade Biosciences
JBIO
$883M
| $29.9M | 4.4% |
62,894
| – | – |
2021 Q4
7 quarters
|
|
|
ICVX
10
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $28.7M | 4.23% |
3,703,704
| – | – |
2023 Q2
1 quarter
|
|
|
11
Compass Pathways
CMPS
$1.55B
| $28.5M | 4.2% |
+3,858,000
| New | +$34.2M |
2023 Q3
0 quarters
|
|
12
DELISTED
Ventyx Biosciences
VTYX
| $28.3M | 4.17% |
815,724
| – | – |
2022 Q4
3 quarters
|
|
13
Tyra Biosciences
TYRA
$1.31B
| $27.4M | 4.03% |
1,989,103
| – | – |
2021 Q4
7 quarters
|
|
14
Madrigal Pharmaceuticals
MDGL
$10.7B
| $26.3M | 3.87% |
179,917
+30,000
| +20% | +$5.65M |
2022 Q3
4 quarters
|
|
15
Silence Therapeutics
SLN
$559M
| $20.7M | 3.04% |
2,104,875
| – | – |
2022 Q3
4 quarters
|
|
16
Tarsus Pharmaceuticals
TARS
$3.49B
| $20.3M | 2.99% |
+1,142,857
| New | +$20.2M |
2023 Q3
0 quarters
|
|
17
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $19.3M | 2.84% |
+869,908
| New | +$18.3M |
2023 Q3
0 quarters
|
|
18
Dyne Therapeutics
DYN
$2.86B
| $14.8M | 2.18% |
1,650,150
| – | – |
2023 Q1
2 quarters
|
|
|
CNTA
19
DELISTED
Centessa Pharmaceuticals
CNTA
| $13.2M | 1.94% |
+2,040,816
| New | +$14M |
2023 Q3
0 quarters
|
|
20
Kura Oncology
KURA
$869M
| $13M | 1.91% |
1,423,642
| – | – |
2022 Q1
6 quarters
|
|
|
21
Immunovant
IMVT
$5.8B
| $12.9M | 1.89% |
334,853
-320,000
| -49% | -$7.23M |
2022 Q4
3 quarters
|
|
22
Entrada Therapeutics
TRDA
$179M
| $9.24M | 1.36% |
584,955
| – | – |
2021 Q4
7 quarters
|
|
|
GRCL
23
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $8.75M | 1.29% |
+3,038,889
| New | +$11.1M |
2023 Q3
0 quarters
|
|
24
Cabaletta Bio
CABA
$263M
| $7.41M | 1.09% |
486,795
| – | – |
2022 Q4
3 quarters
|
|
25
DELISTED
Merus
MRUS
| $7.07M | 1.04% |
300,000
| – | – |
2021 Q4
7 quarters
|
|
Similar funds
CCMIC
TCG Crossover Management's Q3 2023 Portfolio in Review
As of Q3 2023, TCG Crossover Management held 30 positions worth $679M, up 11% from $610M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
TCG Crossover Management deployed $84.1M of net new capital in Q3 2023, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was Inhibrx, Inc. Common Stock: 1,750,387 shares worth $32.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Immunovant, an estimated $7.23M trimmed.
- TCG Crossover Management's largest Q3 2023 buy was Inhibrx, Inc. Common Stock: 1,750,387 shares worth $32.1M.
- TCG Crossover Management added most to Structure Therapeutics in Q3 2023, an estimated $37.1M increase.
- TCG Crossover Management's biggest Q3 2023 reduction was Immunovant, cutting an estimated $7.23M.
- TCG Crossover Management fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $96.3M.
- TCG Crossover Management's ten largest holdings make up 62% of its $679M portfolio in Q3 2023.
- TCG Crossover Management opened 8 new positions and closed 4 in Q3 2023.
- TCG Crossover Management's portfolio value rose 11% quarter-over-quarter to $679M.
Based on TCG Crossover Management's 13F filing for Q3 2023, filed 14 Nov 2023.